% | $
Quotes you view appear here for quick access.

Titan Pharmaceuticals Inc. Message Board

  • pharmas_123 pharmas_123 Nov 9, 2012 9:44 PM Flag

    Key Point

    The outpatient treatment of opioid addiction with daily dosed sublingual buprenorphine formulations represented a $1.3 billion market in the U.S. in 2011, and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011.


    TTNP had successful Phase III results and NDA submitted and asked priority review... and Partnership is behind the scene now.

4.94-0.05(-1.00%)Oct 21 4:00 PMEDT